Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Subscribe To Our Newsletter & Stay Updated